Target intelligence / Profile preview

Mucin–mucin self-interface

Molecular classification
Protein-protein interaction site, Glycoprotein complex
01

Overview

The mucin–mucin self-interface refers to the biochemical and physical contact points between individual mucin glycoproteins, primarily MUC5AC and MUC5B, which facilitate the formation of a complex, viscoelastic gel network (Thornton et al., 2008). This interface is maintained through a combination of covalent disulfide bonds between cysteine-rich D-domains and various non-covalent interactions, including hydrophobic and electrostatic forces (Fahy & Dickey, 2010). In healthy individuals, this gel-forming process is essential for mucociliary clearance and protecting the underlying epithelium from pathogens and irritants (Boucher, 2019). However, in respiratory diseases such as cystic fibrosis and COPD, hyper-polymerization or dehydration leads to pathologically thick mucus that obstructs airways (Ridley et al., 2014). Therapeutic strategies targeting this interface aim to disrupt these interactions using mucolytic agents, such as thiol-based reducers, to decrease mucus viscosity and enhance clearance (Henke, 2010). By breaking the bonds at the self-interface, these drugs help restore normal airway patency and reduce the risk of chronic infection and inflammation (Ehre et al., 2019).

Other names
Mucin polymerization interfaceMucin-mucin interaction siteMucin gel-forming complexMucin cross-linking interface
02

Mechanism of action

Reduction of intermolecular disulfide bonds and disruption of non-covalent interactions between mucin monomers to decrease mucus viscosity (Henke, 2010; Boucher, 2019).

03

Biological functions

Mucus gel formationMucociliary clearanceEpithelial barrier protectionLubrication
04

Disease associations

Cystic fibrosisChronic obstructive pulmonary disease (COPD)AsthmaBronchiectasisChronic bronchitis
05

Safety considerations

BronchospasmAirway irritationDisruption of protective mucosal barriersGastrointestinal distress
06

Interacting drugs

N-acetylcysteine

4 more in the full profile.

07

Biomarkers

Sputum viscosityMUC5AC protein levelsMUC5B protein levelsForced expiratory volume in 1 second (FEV1)Mucus percent solids (Ehre et al., 2019)

Beyond the preview

Go deeper on Mucin–mucin self-interface.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucin–mucin self-interface.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call